The Utility of TH-302 in Sarcoma
Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses the cytotoxic chemotherapy TH-302.
Vicki Keedy, MD, Assistant Professor of Medicine, Clinical Director, Sarcoma Program, Vanderbilt-Ingram Cancer Center, discusses the cytotoxic chemotherapy TH-302.
Clinical Pearls:
- TH-302 is similar to ifosfamide but is a hypoxia-induced agent
- TH-302 targets the large areas of hypoxia found in sarcomas that chemotherapy cannot reach
- A randomized phase III study of Adriamycin (doxorubicin) versus Adriamycin plus TH-302 is undergoing accrual
- The initial phase II data is promising with good progression-free survival data
Related Videos
Related Content
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024Article
In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
